Volpara Solutions Signs Collaboration Agreement with Ambry Genetics

Ambry Genetics, part of Konica Minolta Precision Medicine, developed the CARE (Comprehensive, Assessment, Risk, and Education) Program™.  

Designed to identify high-risk patients through validated risk assessment models and genetic testing, the CARE Program provides clinically actionable results to guide cancer screening, prevention, and effectively communicates this information to patients and their care teams.

Ambry and Volpara are collaborating to incorporate CARE with Volpara's cancer screening platform to automate the workflow by creating an online ordering process for genetic testing within the Aspen® Breast practice management software.

The goal is to help providers obtain the information they need to confidently make informed decisions about their patients' screening options.

The program will include the use of the Volpara®Density™ clinical function to automatically and objectively assess volumetric breast density, a key factor in estimating a woman's risk for developing breast cancer. Risk assessment is often required by insurance companies to confirm reimbursement for supplemental screening and genetic testing.

Patients who qualify for supplemental imaging based on genetic results or risk assessments may benefit from early cancer detection, which is key in increasing the chances of survival and reducing treatment costs.

Volpara software provides radiologists with the clinical decision-support tools they need to personalize breast screening and provide radiologists, administrators, and technologists with the practice management tools they need to improve mammographic quality and maximize resource utilization.

"Personalisation of breast cancer screening based on risk is being adopted at a fast pace in the US, and Volpara is proud to be playing a major role in that.

Our partnership with Ambry will allow us to offer additional value to our customers to ensure the right patients get the right testing at the right time," said Ralph Highnam, Ph.D., Volpara Solutions CEO.

"This partnership highlights the value and the need for precision medicine. Our goal is to elevate the standard of care for patients by providing an individualized approach that will allow doctors and researchers to predict more accurately which treatment and prevention strategies will work for patients, and this partnership is leading that charge," said Tom Schoenherr, Chief Commercial Officer of Ambry Genetics.



Posted by

Join the NZHIT network

The strong network of NZHIT members work collaboratively to provide solutions to enable the health and wellbeing of people living in New Zealand and Globally